CJC-1295 With DAC Research Overview

CJC-1295 With DAC is a synthetic 29-amino-acid analog of growth hormone-releasing hormone (GHRH 1-29) modified with a Drug Affinity Complex (DAC), which extends its systemic half-life. This peptide is primarily utilized in preclinical and in vitro research to study GHRH receptor activation, cAMP/PKA-mediated signaling, and GH-axis modulation in laboratory models.

The peptide is of scientific interest because the DAC modification allows sustained receptor engagement and prolonged GH release in experimental systems, enabling investigations into temporal patterns of GHRH-mediated signaling and downstream molecular effects. Literature on this peptide is limited to supplier technical documentation and preclinical assay studies, as peer-reviewed mechanistic studies are sparse.

---

Mechanism of Action in Laboratory Models

CJC-1295 With DAC has been investigated in preclinical research for its long-acting GHRH receptor agonism:

• GHRH Receptor (GHRH-R) Activation

  • Laboratory studies explore receptor binding and cAMP/PKA intracellular signaling in pituitary somatotroph models.

  • Sustained receptor activation allows experimental modeling of prolonged GH signaling dynamics.

• DAC-Mediated Half-Life Extension

  • The DAC modification promotes reduced clearance in vitro and in vivo models, allowing studies of longer-term GH-axis modulation relative to non-DAC analogs.

• Single-Target Activity

  • Mechanistic investigations focus on GHRH-R without documented pleiotropic receptor effects.

---

Primary Research Findings

Research on CJC-1295 With DAC is primarily preclinical and mechanistic:

• GH Secretion Dynamics

  • Laboratory models indicate sustained GH release consistent with DAC-mediated prolonged peptide circulation.

• Comparative Analyses

  • Studied alongside CJC-1295 Without DAC to explore differences in half-life, receptor engagement, and intracellular signaling duration.

• Metabolic Endpoint Research

  • Used in cellular models of GH-responsive tissues to measure GH-dependent markers, without clinical outcome implications.

Note: Literature is primarily derived from supplier technical documentation and preclinical assay reports; peer-reviewed mechanistic studies are limited.

---

Research Applications

Endocrine and GH-Axis Research

• Investigates long-acting GHRH-R signaling, sustained cAMP/PKA activation, and prolonged GH secretion patterns.

• Experimental endpoints include receptor activation assays, GH quantification, and downstream pathway analyses.

Comparative Peptide Research

• Applied in studies comparing short- vs. long-acting GHRH analogs.

• Supports experimental exploration of pharmacokinetic effects on GH-axis modulation.

Metabolic Research

• Utilized in in vitro hepatocyte and adipocyte models to investigate GH-related intracellular signaling and temporal hormone dynamics.

---

Research Handling and Format

• Lyophilized Powder: Freeze-dried to maintain peptide stability and reproducibility.

• Storage: Keep in a cool, dry, and light-protected environment.

• Reconstitution: Stability post-reconstitution is short-term; conditions may vary across laboratories.

• Research Use Only: Intended solely for preclinical and in vitro research; not for human consumption or clinical use.

---

Peptide Identity and Molecular Profile

---

References

• Literature on CJC-1295 With DAC is primarily preclinical and derived from peptide supplier specifications.

• Verified references on GHRH receptor signaling and DAC effects:

  • Ho, K. Y., & Veldhuis, J. D. (1995). Mechanisms controlling pulsatile GH secretion in laboratory models. Endocrine Reviews, 16(6), 725–757.

  • Peptide supplier technical datasheets provide sequence, molecular weight, and handling information.

Note: Peer-reviewed mechanistic studies for DAC-modified CJC-1295 are limited; most data originate from preclinical assay reports and manufacturer documentation.